Coming soon

Get notified when accounts open

Accounts are not open yet. Leave your email and we will tell you the moment sign-up is available.

UroGen Pharma Ltd. (URGN) institutional ownership

Latest close $45.60 Aug 6, 2026
Market cap$896M 52-week range SectorHealthcare
Funds holding · Q2 2026
0
reported URGN position changes
See ownership breakdown →
Top owners · Q2 2026
No disclosed owners are available.
See all holders →
Institutional activity · Q2 2026
Activity unavailable
No clean comparison
See all activity →

UroGen Pharma Ltd. (URGN) price and institutional activity

Dates

Q2 2026

$0 bought by 0 investors
$0 sold by 0 investors
Bought Sold Totals per quarter; hover a bar for the names.

UroGen Pharma Ltd. (URGN) ownership

Share of total shares outstanding by holder type, in Q2 2026.
No ownership breakdown has been computed for URGN yet.

Largest disclosed holders

Largest disclosed holders in Q2 2026.
No 13F holder is disclosed for URGN in this period.

What UroGen Pharma Ltd. (URGN) paid employees in stock

Stock-based compensation (the accounting cost of shares and options granted to employees), buybacks and share count, from the company's own annual SEC filings.
Stock comp paid to employees, across 10 fiscal years, FY2016 to FY2025
$165M
The accounting cost of the shares and options granted to employees, added up over the fiscal years named in the label.
Cash spent buying its own shares back
No buyback total can be added up for this window. The coverage line below says which fiscal years the company reported one in.
Net buyback
No buyback total can be added up for this window. The coverage line below says which fiscal years the company reported one in.
Share count change
No diluted share count is reported for both ends of this window.
Stock comp as a share of revenue, FY2016 to FY2025
38.0%
How much of every sales dollar was paid to employees in stock, over the fiscal years both figures cover.
Stock comp as a share of buybacks
No buyback total can be added up for this window. The coverage line below says which fiscal years the company reported one in.
Stock comp as a share of operating cash flow
The fiscal years with a stock-comp figure and the fiscal years with a operating cash flow figure do not overlap inside this window, so there is no shared period to compare them over.
Buyback dollars per share actually removed
No diluted share count is reported for both ends of this window.
Fiscal year Stock comp Revenue Diluted shares Change vs prior year
FY2025
Stock comp $12M Revenue $110M
FY2025 $12M $110M
FY2024
Stock comp $13M Revenue $90M
FY2024 $13M $90M
FY2023
Stock comp $9.3M Revenue $83M
FY2023 $9.3M $83M
FY2022
Stock comp $11M Revenue $64M
FY2022 $11M $64M
FY2021
Stock comp $23M Revenue $48M
FY2021 $23M $48M
FY2020
Stock comp $28M Revenue $12M
FY2020 $28M $12M
FY2019
Stock comp $30M Revenue $18K
FY2019 $30M $18K
FY2018
Stock comp $31M Revenue $1.1M
FY2018 $31M $1.1M
FY2017
Stock comp $6.3M Revenue $8.2M
FY2017 $6.3M $8.2M
FY2016
Stock comp $2.0M Revenue $18M
FY2016 $2.0M $18M
10 of 10

Source: the company's own annual SEC filings (XBRL company facts), through FY2025.

UroGen Pharma Ltd. (URGN) institutional activity · 0

No matching institutional activity. Clear the filters to try again.

Famous investor activity in UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. (URGN) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Schoenberg Mark · Officer Sell −$400K
Price $40.00 Qty −10K Owned 120K ΔOwn −7.7% Trade date Jul 9, 2026 Filed date Jul 10, 2026
Schoenberg Mark Officer Sell $40.00 −10K −$400K 120K −7.7% Jul 9, 2026 Jul 10, 2026
Schoenberg Mark · Officer Sell −$350K
Price $35.01 Qty −10K Owned 130K ΔOwn −7.2% Trade date Jun 22, 2026 Filed date Jun 24, 2026
Schoenberg Mark Officer Sell $35.01 −10K −$350K 130K −7.2% Jun 22, 2026 Jun 24, 2026
Wildman Daniel George · Director 2 operations 18K
Owned 8K Trade date Jun 22, 2026 Filed date Jun 24, 2026
Wildman Daniel George
2 fills
  1. Fill 1: – · 10K · – · SEC
  2. Fill 2: – · 8K · – · SEC
Director 2 operations 18K 8K Jun 22, 2026 Jun 24, 2026
Robinson James A. Jr · Director 2 operations 18K
Owned 8K Trade date Jun 22, 2026 Filed date Jun 24, 2026
Robinson James A. Jr
2 fills
  1. Fill 1: – · 10K · – · SEC
  2. Fill 2: – · 8K · – · SEC
Director 2 operations 18K 8K Jun 22, 2026 Jun 24, 2026
Holden Stuart · Director Grant (A) 20K
Owned 20K Trade date Jun 22, 2026 Filed date Jun 24, 2026
Holden Stuart Director Grant (A) 20K 20K Jun 22, 2026 Jun 24, 2026
Butitta Cynthia M. · Director 2 operations 18K
Owned 8K Trade date Jun 22, 2026 Filed date Jun 24, 2026
Butitta Cynthia M.
2 fills
  1. Fill 1: – · 10K · – · SEC
  2. Fill 2: – · 8K · – · SEC
Director 2 operations 18K 8K Jun 22, 2026 Jun 24, 2026
Wen Leana · Director 2 operations 18K
Owned 8K Trade date Jun 22, 2026 Filed date Jun 24, 2026
Wen Leana
2 fills
  1. Fill 1: – · 10K · – · SEC
  2. Fill 2: – · 8K · – · SEC
Director 2 operations 18K 8K Jun 22, 2026 Jun 24, 2026
Belldegrun Arie · Director Grant (A) 20K
Owned 20K Trade date Jun 22, 2026 Filed date Jun 24, 2026
Belldegrun Arie Director Grant (A) 20K 20K Jun 22, 2026 Jun 24, 2026
Schoenberg Mark · Officer Sell −$143K
Price $27.30 Qty −5K Owned 140K Trade date Jun 8, 2026 Filed date Jun 9, 2026
Schoenberg Mark Officer Sell $27.30 −5K −$143K 140K Jun 8, 2026 Jun 9, 2026
Schoenberg Mark · Officer 2 operations 0
Owned 0 Trade date Jun 8, 2026 Filed date Jun 9, 2026
Schoenberg Mark
2 fills
  1. Fill 1: – · 10K · – · SEC
  2. Fill 2: – · −10K · – · SEC
Officer 2 operations 0 0 Jun 8, 2026 Jun 9, 2026
Robinson James A. Jr · Director 2 operations 0
Owned 2K Trade date May 26, 2026 Filed date May 27, 2026
Robinson James A. Jr
2 fills
  1. Fill 1: – · 2K · – · SEC
  2. Fill 2: – · −2K · – · SEC
Director 2 operations 0 2K May 26, 2026 May 27, 2026
Schoenberg Mark · Officer Sell −$300K
Price $30.00 Qty −10K Owned 135K Trade date May 8, 2026 Filed date May 11, 2026
Schoenberg Mark Officer Sell $30.00 −10K −$300K 135K May 8, 2026 May 11, 2026
Smith Jason Drew · Officer 3 operations −$147K
Price $19.69 Qty −7K Owned 53K Trade date Feb 3, 2026 Filed date Feb 11, 2026
Smith Jason Drew
3 fills
  1. Fill 1: $19.69 · −3K · −$63K · SEC
  2. Fill 2: $19.69 · −2K · −$32K · SEC
  3. Fill 3: $19.69 · −3K · −$52K · SEC
Officer 3 operations $19.69 −7K −$147K 53K Feb 3, 2026 Feb 11, 2026
Schoenberg Mark · Officer 3 operations −$145K
Price $19.69 Qty −7K Owned 151K Trade date Feb 3, 2026 Filed date Feb 4, 2026
Schoenberg Mark
3 fills
  1. Fill 1: $19.69 · −2K · −$36K · SEC
  2. Fill 2: $19.69 · −4K · −$73K · SEC
  3. Fill 3: $19.69 · −2K · −$36K · SEC
Officer 3 operations $19.69 −7K −$145K 151K Feb 3, 2026 Feb 4, 2026
Barrett Elizabeth A. · Officer Grant (A) 153K
Owned 153K Trade date Jan 31, 2026 Filed date Feb 19, 2026
Barrett Elizabeth A. Officer Grant (A) 153K 153K Jan 31, 2026 Feb 19, 2026
15 of 39 Get notified: all 39 insider filings

UroGen Pharma Ltd. (URGN) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Rtw Investments, LP 4.9M
% of shares outstanding 10.0% Filing date Nov 14, 2024
Rtw Investments, LP 4.9M 10.0% Nov 14, 2024
Adage Capital Management, L.P. 3.7M
% of shares outstanding 8.9% Filing date Nov 12, 2024
Adage Capital Management, L.P. 3.7M 8.9% Nov 12, 2024
Ra Capital Management, L.P. 3.2M
% of shares outstanding 7.1% Filing date Nov 14, 2024
Ra Capital Management, L.P. 3.2M 7.1% Nov 14, 2024
Blackrock, Inc. 2.5M
% of shares outstanding 5.9% Filing date Nov 8, 2024
Blackrock, Inc. 2.5M 5.9% Nov 8, 2024
Menora Mivtachim Holdings Ltd. 2.3M
% of shares outstanding 5.5% Filing date Nov 14, 2024
Menora Mivtachim Holdings Ltd. 2.3M 5.5% Nov 14, 2024
The Toronto-Dominion Bank 2.6M
% of shares outstanding 5.4% Filing date May 15, 2026
The Toronto-Dominion Bank 2.6M 5.4% May 15, 2026
Blackrock, Inc. 2.5M
% of shares outstanding 5.2% Filing date Apr 27, 2026
Blackrock, Inc. 2.5M 5.2% Apr 27, 2026
Morgan Stanley 2.2M
% of shares outstanding 5.2% Filing date Nov 6, 2024
Morgan Stanley 2.2M 5.2% Nov 6, 2024
8 of 15

UroGen Pharma Ltd. (URGN) ownership FAQ

Who owns URGN?

0 reporting institutions disclosed URGN position changes in the Q2 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q2 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.